Page 1

Rhelion Life Sciences Reports First Quarter 2027 Results Toronto , Ontario -- ( Newsfile Corp. - August 31 , 2026 ) - Rhelion Life Sciences Corp. ( CSE : RHEL ) ( FSE : 4YX0 ) ( OTCQB : TRUFF ) ( " Rhelion " or the " Company " ) , an Ontario - based organization advancing innovation and research within the legal psychedelic sector , is pleased to report its financial and operational results for the three months ended June 30 , 2026 ( " Q1 2027 " ) , capping a transitional quarter which culminated in the acquisition of Filament Health Corp. ( " Filament " ) . All figures are reported in Canadian dollars . The full set of the Company's unaudited condensed interim consolidated financial statements and accompanying management's discussions and analysis can be accessed by visiting the Company's website at www.Rhelion.com and its profile page on SEDAR + at www.sedarplus.ca . Q1 2027 Marks the Beginning of Rhelion's New Life Sciences Platform The first quarter of Fiscal 2027 marked a significant transition for Rhelion following the completion of its acquisition of Filament on April 29 , 2026. The acquisition added pharmaceutical drug development , GMP manufacturing , regulatory , clinical supply and intellectual property capabilities to the Company and shifted Rhelion's strategic focus toward the research and development ( " R & D " ) of naturally derived psychedelic medicines . Through Filament , Rhelion is advancing PEX010 , its patented , standardized , naturally derived psilocybin drug candidate , while continuing to support academic and clinical research programs around the world . The Company intends to leverage Filament's pharmaceutical development , manufacturing , regulatory and intellectual property capabilities to advance its drug development platform , expand regulated clinical and research supply opportunities and evaluate additional naturally derived drug candidates . Rhelion believes the combination of Filament's scientific and pharmaceutical capabilities with the Company's existing resources provides a strong foundation from which to build a focused and differentiated life sciences platform . Todd Shapiro , Chief Executive Officer and Director of Rhelion , commented : " The first quarter of Fiscal 2027 represents an important inflection point for Rhelion as we begin executing on the strategy created through our acquisition of Filament . The combination brings together pharmaceutical R & D , GMP manufacturing , regulatory capabilities , intellectual property and global clinical research supply under one platform . We believe this gives Rhelion a strong foundation to pursue opportunities in naturally derived psychedelic medicines and build a differentiated life sciences company . At the centre of this platform is PEX010 , Filament's patented , standardized and GMP - manufactured botanical psilocybin drug candidate . We are encouraged by the continued interest from academic and clinical researchers and by the growing number of institutions evaluating PEX010 across different research settings and therapeutic areas . We believe the ability to provide researchers with a standardized , pharmaceutical - grade botanical psilocybin drug candidate represents an important competitive advantage as psychedelic drug development continues to evolve . PEX010's existing body of clinical research and safety data also provides Rhelion with a strong foundation as we evaluate opportunities to advance our own clinical development programs utilizing the potential unique advantages of our patented botanical psilocybin extract . " Expanding the Naturally Derived Drug Development Pipeline